Table 1.
Discovery (n=201) | Validation (n=202) | Total (n=403) | ||
---|---|---|---|---|
Sex, F/M (% male) | 71/130 (54.6%) | 71/131(54.2%) | 142/261 (54.4%) | |
| ||||
Age (yrs) | Mean ± SD | 60.94 ± 9.55 | 60.93 ± 8.82 | 60.93 ± 9.18 |
Range | 36 – 78 | 34 – 79 | 34 – 79 | |
| ||||
Disease Duration (yrs) | Mean ± SD | 1.99 ± 1.33 | 2.08 ± 1.38 | 2.04 ± 1.36 |
Range | 0 – 6 | 0 – 7 | 0 – 7 | |
| ||||
MMSE | Mean ± SD | 28.78 ± 1.48 | 28.97 ± 1.41 | 28.87 ± 1.45 |
Range | 23 – 30 | 23 – 30 | 23–30 | |
| ||||
UPDRS total | Mean ± SD | 25.77 ± 11.10 | 22.91 ± 12.17 | 24.34± 11.72 |
Range | 7 – 61 | 0 – 63 | 0 – 63 | |
| ||||
UPDRS motor | Mean ± SD | 17.15 ± 8.46 | 15.47 ± 9.10 | 16.31± 8.82 |
Range | 3 – 50 | 0 – 46 | 0–50 | |
| ||||
Hoehn and Yahr | Median | 1.5 | 1.5 | 1.5 |
Range | 1 – 3 | 1 – 3 | 1 – 3 | |
| ||||
CSF Aβ42 (pg/mL) | Mean ± SD | 233.98 ± 78.63 | 238.29 ± 71.32 | 236.14 ± 74.99 |
Range | 52.14 – 670.08 | 74.77 – 435.72 | 52.14–670.08 | |
| ||||
CSF t-tau (pg/mL) | Mean ± SD | 47.27 ± 25.90 | 46.79 ± 25.07 | 47.03 ± 25.45 |
Range | 13.97 – 146.91 | 10.72 – 213.58 | 10.72 – 213.58 | |
| ||||
CSF p-tau (pg/mL) | Mean ± SD | 23.23 ± 11.66 | 23.44 ± 12.14 | 23.34 ± 11.89 |
Range | 4.56 – 88.02 | 3.99 – 93.11 | 3.99 – 93.11 | |
| ||||
CSF p-tau/t-tau | Mean ± SD | 0.54 ± 0.21 | 0.54 ± 0.21 | 0.54 ± 0.21 |
Range | 0.14 – 1.06 | 0.14 – 1.06 | 0.14 – 1.06 | |
| ||||
CSF t-tau/Aβ42 | Mean ± SD | 0.21 ± 0.11 | 0.21 ± 0.13 | 0.21 ± 0.12 |
Range | 0.08 – 0.71 | 0.09 – 1.21 | 0.08 – 1.21 | |
| ||||
CSF p-tau/Aβ42 | Mean ± SD | 0.11 ± 0.06 | 0.11 ± 0.07 | 0.11 ± 0.06 |
Range | 0.03 – 0.42 | 0.02 – 0.55 | 0.02 – 0.55 |
UPDRS: Unified Parkinson Disease Rating Scale; MMSE Mini Mental State Examination; Aβ1-42: amyloid beta peptide 1-42; CSF: cerebrospinal fluid; p-tau: phosphorylated tau; t-tau: total tau